Scarica l'app Stockscreener
170.44
1.67%
2.80
Precedente Chiudi:
$167.64
Aprire:
$167.56
Volume 24 ore:
1.73M
Relative Volume:
1.70
Capitalizzazione di mercato:
$8.39B
Reddito:
$4.06B
Utile/perdita netta:
$413.08M
Rapporto P/E:
21.28
EPS:
8.01
Flusso di cassa netto:
$560.48M
1 W Prestazione:
+4.73%
1M Prestazione:
-13.50%
6M Prestazione:
+24.65%
1 anno Prestazione:
-12.94%
Intervallo 1D:
$167.45
$171.72
Intervallo di 1 settimana:
$156.72
$172.39
Portata 52W:
$91.86
$203.01
Charles River Laboratories International Inc Stock (CRL) Company Profile
Nome
Charles River Laboratories International Inc
Settore
Industria
Telefono
781-222-6000
Indirizzo
251 BALLARDVALE ST, WILMINGTON, MA
Confronta CRL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
170.44 | 8.25B | 4.06B | 413.08M | 560.48M | 8.01 |
|
TMO
Thermo Fisher Scientific Inc
|
586.07 | 220.72B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
226.98 | 160.62B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
752.14 | 57.96B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
153.60 | 42.88B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
228.18 | 38.30B | 15.90B | 1.28B | 2.21B | 7.2842 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-17 | Aggiornamento | Argus | Hold → Buy |
| 2025-11-06 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2025-10-06 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2025-10-02 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-09-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-07-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-05-23 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | Aggiornamento | TD Cowen | Hold → Buy |
| 2025-05-08 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-03-21 | Downgrade | Goldman | Buy → Neutral |
| 2025-03-04 | Aggiornamento | Citigroup | Sell → Neutral |
| 2025-03-03 | Aggiornamento | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | Downgrade | UBS | Buy → Neutral |
| 2024-11-18 | Downgrade | CLSA | Hold → Underperform |
| 2024-11-07 | Aggiornamento | CLSA | Underperform → Hold |
| 2024-10-23 | Iniziato | CLSA | Underperform |
| 2024-10-14 | Iniziato | Redburn Atlantic | Sell |
| 2024-10-07 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-10-02 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-10-01 | Downgrade | Citigroup | Neutral → Sell |
| 2024-08-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-08-08 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | Downgrade | Argus | Buy → Hold |
| 2024-06-07 | Iniziato | Mizuho | Neutral |
| 2024-06-06 | Iniziato | Goldman | Buy |
| 2024-02-15 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-09-13 | Iniziato | TD Cowen | Market Perform |
| 2023-07-10 | Downgrade | Citigroup | Buy → Neutral |
| 2023-02-23 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-01-12 | Downgrade | Jefferies | Buy → Hold |
| 2022-09-30 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-08-04 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | Iniziato | Guggenheim | Neutral |
| 2022-04-25 | Downgrade | Jefferies | Buy → Hold |
| 2022-04-07 | Iniziato | Stephens | Overweight |
| 2022-02-17 | Reiterato | BofA Securities | Buy |
| 2022-02-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-02-17 | Reiterato | Deutsche Bank | Buy |
| 2022-02-17 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-17 | Reiterato | UBS | Buy |
| 2021-08-05 | Ripresa | Credit Suisse | Neutral |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-09-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-07-01 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-05-13 | Aggiornamento | UBS | Neutral → Buy |
| 2020-04-21 | Downgrade | Jefferies | Buy → Hold |
| 2020-03-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | Iniziato | Deutsche Bank | Buy |
| 2020-02-18 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-01-08 | Iniziato | Wells Fargo | Overweight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-10-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | Iniziato | SVB Leerink | Outperform |
| 2019-04-30 | Ripresa | Evercore ISI | Outperform |
| 2018-12-14 | Iniziato | Deutsche Bank | Buy |
| 2018-10-09 | Iniziato | UBS | Neutral |
| 2018-08-23 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | Aggiornamento | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | Aggiornamento | SunTrust | Hold → Buy |
Mostra tutto
Charles River Laboratories International Inc Borsa (CRL) Ultime notizie
Charles River Laboratories Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Charles River Laboratories International, Inc.CRL - The AI Journal
What Makes Charles River Laboratories (CRL) an Investment Bet? - Insider Monkey
How Does Charles River (CRL) Balance Cautious Guidance with Outperforming Q3 Results? - simplywall.st
Does Charles River’s Lowered Guidance After a Strong Quarter Signal Shifting Priorities for CRL? - Yahoo Finance
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
Barclays Maintains Charles River Laboratories International (CRL) Overweight Recommendation - MSN
Charles River Laboratories Stock: Is Wall Street Bullish or Bearish? - MSN
Redburn Upgrades Charles River Laboratories (CRL) to Buy, Cuts PT - MSN
Will Charles River Laboratories International Inc. stock outperform Dow JonesCPI Data & Reliable Breakout Forecasts - newser.com
Will Charles River Laboratories International Inc. stock benefit from Fed rate cutsEntry Point & Weekly High Potential Alerts - newser.com
Is Charles River Laboratories International Inc. stock undervalued by metricsMarket Weekly Review & Daily Growth Stock Investment Tips - newser.com
CRLCharles Riv Labs Intl Inc Latest Stock News & Market Updates - Stock Titan
Will Charles River Laboratories International Inc. stock see PE expansionJuly 2025 PostEarnings & Consistent Return Investment Signals - newser.com
How Charles River Laboratories International Inc. (RV6) stock valuation compares with sectorTrade Volume Report & Low Risk Profit Maximizing Plans - newser.com
Using RSI to spot recovery in Charles River Laboratories International Inc.Weekly Trade Report & Weekly Breakout Watchlists - newser.com
What does recent volatility data suggest for Charles River Laboratories International Inc.Entry Point & Advanced Technical Signal Analysis - newser.com
Will Charles River Laboratories International Inc. (RV6) stock announce special dividendJuly 2025 Macro Moves & Weekly Consistent Profit Watchlists - newser.com
How strong is Charles River Laboratories International Inc. (RV6) stock earnings growthMarket Activity Recap & Real-Time Market Trend Scan - newser.com
Is Charles River Laboratories International Inc. stock attractive for dividend growthJuly 2025 Summary & Free Daily Entry Point Trade Alerts - newser.com
Can Charles River Laboratories International Inc. (RV6) stock deliver consistent EPS growth - newser.com
Charles River Laboratories International (MEX:CRL) Total Pa - GuruFocus
Charles River Laboratories International Stock: High Cash FlowWhy Not Watch It? - Trefis
Will Charles River Laboratories International Inc. stock see valuation expansion2025 Price Action Summary & Low Risk Entry Point Tips - newser.com
Visual analytics tools that track Charles River Laboratories International Inc. performanceJuly 2025 PostEarnings & Weekly Chart Analysis and Guides - newser.com
Will Charles River Laboratories International Inc. stock benefit from green energy trends2025 Macro Impact & Daily Entry Point Trade Alerts - newser.com
Is Charles River Laboratories International Inc. stock vulnerable to rate hikesWeekly Loss Report & Reliable Intraday Trade Plans - newser.com
Charles River Laboratories gets all-clear in monkey smuggling probe - NBC Boston
Charles River Laboratories gets all-clear from SEC in monkey smuggling probe - The Business Journals
Charles River Laboratories (CRL): Assessing Valuation After Latest Share Price Pullback - simplywall.st
Transcript : Charles River Laboratories International, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 11 - MarketScreener
CRL: Biotech bookings rebound, pricing stabilizes, and cost-saving drives margin protection - TradingView
Charles River (CRL) International Revenue Performance Explored - sharewise.com
Quick ratio of Charles River Laboratories International, Inc. – HAM:RV6 - TradingView
Will Charles River Laboratories International Inc. (RV6) stock split increase liquidityGold Moves & Risk Controlled Stock Alerts - newser.com
What macro factors could drive Charles River Laboratories International Inc. (RV6) stock higher2025 Trading Volume Trends & Safe Entry Zone Identification - newser.com
Charles River Laboratories, US SEC end investigations into primate shipments - MLex
Charles River Laboratories International Inc. stock underperforms Monday when compared to competitors - MarketWatch
Charles River Laboratories International Inc Azioni (CRL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.35%
1.41%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):